Open AccessMycophenolate mofetil or standard therapy for membranous nephropathy and focal segmental glomerulosclerosis: a pilot study
Author(s) -
L. Senthil Nayagam,
Arijit Ganguli,
Manish Rathi,
Harbir Singh Kohli,
K. L. Gupta,
Kamaldeep Joshi,
V. Sakhuja,
Vivekanand Jha
Publication year - 2007
Publication title -
nephrology dialysis transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.654
H-Index - 168
eISSN - 1460-2385
pISSN - 0931-0509
DOI - 10.1093/ndt/gfm538
Subject(s) - medicine , focal segmental glomerulosclerosis , prednisolone , membranous nephropathy , urology , nephrotic syndrome , gastroenterology , minimal change disease , cyclophosphamide , creatinine , proteinuria , surgery , chemotherapy , kidney
The current treatment regimes for patients with nephrotic syndrome due to idiopathic membranous nephropathy (MN) and focal segmental glomerulosclerosis (FSGS) are based on steroids and/or cytotoxic agents. Data on the effect of mycophenolate mofetil (MMF) for these conditions are scarce and confounding.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom